BioBeat

BioBeat is a medical technology company established in 2016 in Petah Tikva, Israel, by Arik Ben Ishay, Johanan May, and Israel Sarussi. The company's creation was spurred by CEO Arik Ben Ishay's experience as a volunteer paramedic during the 2014 Israel-Gaza conflict, where he identified a critical need for effective field-ready vital sign monitoring. This firsthand experience, combined with Sarussi's expertise in reflective photoplethysmography (PPG) technology and May's background in IoT and R&D management, formed the foundation of the company. Ben Ishay previously managed technological projects at the Israeli Ministry of Defense, while Sarussi has over 40 years of experience developing high-tech medical devices.

BioBeat operates in the remote patient monitoring (RPM) market, serving healthcare providers in hospitals, long-term care facilities, and pharmaceutical companies conducting clinical trials. Its business model revolves around providing a comprehensive platform that includes wearable monitoring devices and a cloud-based patient management system. The company generates revenue through the sale of its devices and likely through subscription access to its data platform and analytics. A key achievement for BioBeat was becoming the first company to receive FDA clearance for cuffless blood pressure monitoring using only a PPG sensor in 2019. Since then, it has secured further FDA clearances for a total of seven metrics, including blood oxygen saturation, pulse rate, respiratory rate, body temperature, stroke volume, and cardiac output.

The company offers two main wearable devices: a disposable short-term chest monitor and a reusable long-term wrist monitor. These devices continuously collect patient data, tracking up to 13 health parameters. The data is transmitted in real-time to a secure, HIPAA and GDPR compliant cloud platform. This platform features an AI-powered early warning score (EWS) system that analyzes the data to provide alerts on potential patient deterioration, enabling timely clinical intervention. For consumers, BioBeat has also introduced a direct-to-consumer, single-use chest patch kit for 24-hour blood pressure monitoring. The company has formed strategic partnerships, including an integration with Best Buy Health's Current Health platform to expand its reach in the care-at-home market.

Keywords: remote patient monitoring, wearable medical devices, cuffless blood pressure, vital signs monitoring, photoplethysmography (PPG), healthcare AI, patient data analytics, FDA cleared medical device, chest monitor, wrist monitor, continuous monitoring, early warning score system, hospital at home, telehealth solutions, medical-grade wearables, cardiac output monitoring, stroke volume monitoring, respiratory rate tracking, blood oxygen saturation, real-time health data